Megan Baldwin
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Megan Baldwin
Chief Executive, Managing Director since 2015 / Opthea
Dr Megan Baldwin has over 20 years of experience in angiogenesis and therapeutic strategies for cancer and ophthalmic indications.
Her experience included several years as a researcher in the group of leading angiogenesis expert Napoleone Ferrara, before moving to Genentech's commercial division and having responsibility for corporate competitive intelligence activities. She has developed commercial and scientific knowledge in the field of anti-angiogenic and oncology drug development.
Her experience included several years as a researcher in the group of leading angiogenesis expert Napoleone Ferrara, before moving to Genentech's commercial division and having responsibility for corporate competitive intelligence activities. She has developed commercial and scientific knowledge in the field of anti-angiogenic and oncology drug development.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1002nd | Opthea | -19% | -2% |
| 1113th | QuickFee | -26% | |
| 1329th | Zoono Group | -41% | -13% |
| 1370th | 8Common | -43% | 3% |
| 1809th | Galilee Energy | -76% | -39% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 700th |  | Opthea | $19.1m |
| 816th | | Galilee Energy | $7.8m |
| 817th | | Zoono Group | $7.8m |
| 819th | | QuickFee | $7.6m |
| 821st | | 8Common | $7.5m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Chief Executive, Managing Director since 2015, Opthea | 03 Nov 2020 |
